Opinion/decision on a Paediatric investigation plan (PIP): Yorvipath, palopegteriparatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: EMA/PE/0000241327

Submitted by Anonymous (not verified) on 7 July 2026 - 14:46

Opinion/decision on a Paediatric investigation plan (PIP): Yorvipath, palopegteriparatide, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Endocrine disorders, PIP number: EMA/PE/0000241327

Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: EMA/PE/000024

Submitted by Anonymous (not verified) on 7 July 2026 - 14:38

Opinion/decision on a Paediatric investigation plan (PIP): Briviact (in Italy: Nubriveo), Brivaracetam, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders, PIP number: EMA/PE/0000240232

Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine hydrochloride,dolutegravir sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number:

Submitted by Anonymous (not verified) on 7 July 2026 - 14:36

Opinion/decision on a Paediatric investigation plan (PIP): Juluca, rilpivirine hydrochloride,dolutegravir sodium, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000240971

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Latest Newsletters

More
randomness